TS-068290 — The Need Radiation exposure poses significant health risks, including cancer and other illnesses, making it crucial for clinicians to accurately measure and assess the extent of radiation exposure. Existing methods often require invasive procedures and may not detect exposure at lower dose ranges. …

TS-068081 — These RAFT agents enable synthesis of novel polymer materials with enhanced biocompatibility and tailored functionality, suited for a wide range of biomedical applications.

TS-066751 — In the rapidly evolving field of biotechnology and pharmaceuticals, there is a critical need for efficient delivery mechanisms to transport therapeutic agents directly into cells. Traditional methods face challenges with membrane impermeability and degradation of therapeutic compounds, limiting th…

TS-065862 — The Need In the landscape of cancer treatment, the emergence of immunotherapy has shown remarkable promise. However, its efficacy is not universal across all cancer types, and resistance development poses a significant challenge. Hyperprogression, characterized by accelerated tumor growth, further …

TS-065457 — The Need: In the realm of therapeutic development, there's a pressing need for precise targeting of dysregulated ribonucleoprotein (RNP) complexes to combat various diseases, particularly neurodegenerative disorders like ALS, Alzheimer’s, and Huntington’s diseases. Traditional metho…

TS-064834 — The Need: Colorectal cancer remains a significant global health challenge, particularly when it metastasizes to the liver. Accurate and rapid diagnosis of metastatic liver lesions is crucial for effective treatment planning and patient outcomes. Traditional diagnostic methods often lack the specific…

TS-064581 — Antibodies are essential therapeutic modalities for treating a plethora of different diseases, ranging from cancer, autoimmune disorders, degenerative diseases, and inflammation. The FDA approved the first antibody over three decades ago, and since more than 570 have been studied in clinical trials,…

TS-064577 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately only 40% living past the first-year post-diagnosis and 17% in the second year. The Need Developing drugs for cance…

TS-064262 — The Need Addressing the limitations of current melanoma therapies, there exists a critical need for innovative approaches that enhance the effectiveness of immune checkpoint therapeutics. Despite advancements in immunotherapy, a significant percentage of melanoma patients do not achieve complete re…

TS-064179 — In the realm of medical diagnostics, the need for precise and non-invasive detection of molecular-level pathology has been a longstanding challenge. Traditional imaging techniques often fall short in providing detailed insights into biological processes at this scale. To address this gap, there is…